Pharmapress

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pharmapress

Quick Facts

Property Description
Active ingredient Enalapril maleate
Form Oral tablets
Pharmacological class Angiotensin-Converting Enzyme Inhibitors (ACE inhibitors)
General purpose Manages conditions involving high vascular strain
Origin Synthetic compound (Prodrug)

What is Pharmapress and Its Drug Class?

Pharmapress is a prescription-only medicine containing the active compound Enalapril maleate, classified as a core cardiovascular medicine. The drug is a synthetic compound that belongs specifically to the potent class of Angiotensin-Converting Enzyme Inhibitors (ACE inhibitors).

Enalapril is categorized as a prodrug administered via the oral route, meaning it is chemically inactive upon ingestion and must be metabolized by the body into its active form, Enalaprilat, before its therapeutic effects can begin. The medication's mechanism of action is focused on modulating the Renin-Angiotensin-Aldosterone System (RAAS), a crucial pathway that regulates fluid balance and blood pressure.

Composition, Form, and General Purpose

Pharmapress is supplied as an oral solid preparation in the form of tablets, and is formulated as a single-ingredient product. Its general function is defined by its role as an antihypertensive agent.

By inhibiting the ACE enzyme, the medication promotes widespread vessel relaxation and widening, which reduces the resistance within the circulatory system. This reduction in the overall resistance is a primary function of the medication. This effect consequently lowers blood pressure and decreases the heart workload, facilitating smoother circulation and easing chronic strain on the cardiovascular system.

Regulatory References

  1. ACE Inhibitor therapy from MedlinePlus

What side effects are possible with Pharmapress?

Adverse Reactions and Safety Profile

Pharmapress (enalapril maleate) is an Angiotensin-Converting Enzyme (ACE) inhibitor whose safety profile is well-documented in regulatory sources. Adverse reactions are classified by frequency and involvement of system-organ classes including the nervous system, respiratory system, gastrointestinal system, and skin.

Adverse Reaction Frequency (Based on Regulatory Classification)

Classification Examples of Documented Reactions
Very Common (1/10) Cough, Dizziness, Asthenia (weakness)
Common (1/100 to < 1/10) Headache, Depression, Syncope, Hypotension (including orthostatic), Fatigue, Diarrhoea, Nausea, Rash, Hyperkalaemia, Increased serum creatinine
Uncommon (1/1,000 to < 1/100) Myocardial infarction or cerebrovascular accident (secondary to excessive hypotension), Renal failure/dysfunction, Anemia, Hepatitis/Jaundice
Rare (1/10,000 to < 1/1,000) Hepatic failure, Fulminant hepatic necrosis, Agranulocytosis, Stevens-Johnson syndrome

Serious Safety Considerations

The most serious safety concerns documented are Angioedema (swelling of the face, extremities, lips, tongue, glottis, and/or larynx, which can be fatal) and Fetal Toxicity. Regulatory warnings strictly prohibit the use of Pharmapress during the second and third trimesters of pregnancy due to the risk of fetal morbidity and death. Symptomatic Hypotension, particularly after the initial dose in volume-depleted patients, and Renal Failure (especially in patients with severe heart failure or underlying renal disease like renal artery stenosis) are also highlighted risks. High potassium levels (Hyperkalaemia) are a common finding requiring monitoring, particularly in patients with pre-existing renal impairment or those on concomitant potassium-sparing agents. Caution is also advised for patients of black ethnicity due to a potentially higher incidence of angioedema. Pharmapress is contraindicated in patients with a history of angioedema related to ACE inhibitor therapy.

Overdose and Emergency Response

Overdose: When to Seek Immediate Medical Help

This information is based on official government regulatory documents regarding the overdose profile of enalapril (Pharmapress).

Documented Overdose Presentations

Taking more than the prescribed dose may result in severe, life-threatening symptoms, requiring immediate medical intervention. The primary documented clinical manifestations of overdose include:

  • Profound Hypotension: An excessive drop in blood pressure.
  • Circulatory Shock: A potentially fatal condition resulting from severe hypotension.
  • Central Nervous System Effects: Symptoms such as sleepiness, dizziness, stupor, and loss of consciousness.
  • Cardiovascular Effects: Pounding heart (palpitations) and potential for changes in heart rhythm.

Required Emergency Actions and Management

Action Area Official Regulatory Statement
Immediate Action Call emergency services or a poison control center immediately. Do not delay seeking medical attention.
Patient Positioning Medical personnel should place the affected individual in a supine (flat on back) position.
Supportive Care Management focuses on correcting hypotension, often through the administration of an intravenous infusion of normal saline (volume expansion).
Metabolite Removal In cases of severe overdosage, hemodialysis is an authorized medical procedure that may be utilized to remove the active metabolite from the body.

Overdose Risk Factors

Patients who are volume-depleted (due to high-dose diuretics, excessive vomiting, or diarrhea) are noted to be at increased risk of experiencing severe hypotensive responses if an overdose occurs.

Therapeutic Uses of Pharmapress

What Pharmapress Treats: Main Uses and Benefits

Pharmapress is commonly used for conditions associated with chronic high blood pressure (hypertension), symptomatic heart failure, and for assisting with the symptomatic management of progressive heart issues.

This medicine is relevant as it helps address symptoms that create noticeable physiological strain and is used across indications including chronic hypertension, symptomatic heart failure, and to manage heart weakness before symptoms appear (asymptomatic left ventricular dysfunction) and diabetic kidney disease. In situations involving significant cardiac functional stress, Pharmapress is commonly used to help with symptoms related to systemic imbalance, particularly fluid accumulation (edema) and effort-related exhaustion.

“This therapeutic approach is commonly used for patients, as it assists with maintaining functional stability and supports the patient during difficult episodes by easing distress.”

It provides supportive relief that helps patients cope more steadily, contributing to improved day-to-day comfort and supporting physical capacity. It may also assist in slowing the rate at which silent damage progresses to overt disease.


Quick Fact: Relief for Fluid Accumulation

Pharmapress helps manage symptoms of systemic imbalance associated with heart failure, such as swelling in the lower extremities.

Eligibility and Restrictions for Use

Who can and cannot use Pharmapress? — Official Regulatory Information

This section outlines the eligibility for Pharmapress (enalapril), strictly based on governmental regulatory documents.


Populations for Whom Use is Prohibited (Contraindications)

Pharmapress must not be used in the following populations or clinical states:

  • Patients with a known hypersensitivity or allergy to enalapril, any other ACE inhibitor, or any component of the formulation.
  • Individuals with a history of angioedema (severe swelling) related to previous ACE inhibitor or ARB therapy, or those with hereditary or idiopathic angioedema.
  • During the second and third trimesters of pregnancy.
  • Patients receiving the combination drug sacubitril/valsartan; Pharmapress use is prohibited within 36 hours of the last dose.
  • Concomitant use with aliskiren in patients with diabetes or moderate to severe kidney impairment (GFR < 60 mL/min/1.73 m^2).
  • Patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney.

Populations Requiring Special Consideration

Use of Pharmapress requires special consideration and dosage adjustment in patients with kidney impairment (renal function issues) or liver impairment (hepatic issues). Use is not recommended in neonates (children younger than 1 month) or in pediatric patients with severe kidney disease (GFR < 30 mL/min/1.73 m^2). Use during breastfeeding is generally not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pharmapress, a combination of an ACE inhibitor and a diuretic, has several clinically significant interactions documented in regulatory labeling. These interactions are categorized based on their severity and the mechanism of effect.

Contraindicated Combinations

The most severe restriction involves Neprilysin (NEP) inhibitors (e.g., sacubitril/valsartan), which are strictly prohibited due to a high risk of angioedema; a minimum 36-hour separation period is required. Aliskiren-containing products are also contraindicated in patients with diabetes mellitus or renal impairment.

Significant Pharmacodynamic and Pharmacokinetic Interactions

Interacting Substance/Class Documented Effect / Constraint
Agents Increasing Serum Potassium (e.g., potassium supplements, potassium-sparing diuretics) High risk of hyperkalemia (elevated blood potassium levels) due to additive effects.
Lithium Reduces lithium's renal clearance, causing increased serum lithium levels and toxicity risk. Monitoring is required.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May diminish the blood pressure-lowering effect and increase the risk of renal function deterioration.
mTOR Inhibitors and Racecadotril Increased risk of angioedema when co-administered.
Alcohol Potentiates the hypotensive effect, which may lead to dizziness or lightheadedness.

These interactions necessitate careful review of a patient's current medication profile prior to starting Pharmapress therapy.

Mechanism of Action

Pharmapress is a prodrug that undergoes hepatic bioactivation via hydrolysis to its active metabolite, enalaprilat. Enalaprilat functions as a potent, competitive inhibitor of Angiotensin-Converting Enzyme (ACE), a peptidyl dipeptidase. ACE is a key biological target expressed in various tissues, notably the vascular endothelium of the lungs and kidneys.

The primary molecular consequence of ACE inhibition is the disruption of the Renin-Angiotensin-Aldosterone System (RAAS). This disruption prevents the conversion of the inactive decapeptide angiotensin I to the highly vasoactive octapeptide angiotensin II. Decreased plasma levels of angiotensin II lead to reduced stimulation of AT1 receptors on vascular smooth muscle, resulting in vasodilation and a subsequent reduction in total peripheral resistance. Intracellularly, reduced angiotensin II also diminishes stimulation of the adrenal cortex, leading to decreased secretion of aldosterone. This reduction in aldosterone modulates the renal distal tubules and collecting ducts, decreasing the reabsorption of sodium ions and water. The downstream cascade also involves the accumulation of bradykinin, a potent vasodilator peptide normally degraded by ACE (also known as kininase II). The system-level physiological consequences are a decrease in systemic arterial blood pressure and a modulated blood volume and electrolyte balance.

Dosage and Administration Information

How to Use Pharmapress: Administration Guidelines

Pharmapress (enalapril maleate) is an angiotensin-converting enzyme (ACE) inhibitor. The following administration details and procedural instructions outline the standard administration of the medication.

Administration Details

Feature Instruction
Route & Form Administered orally as a tablet. The active metabolite, enalaprilat, is available for intravenous (IV) administration.
Timing with Food May be taken with or without food, as the presence of food does not clinically affect its absorption.
Standard Dosing Hypertension: The usual starting dose is 10 mg to 20 mg taken once daily. Heart Failure: Therapy begins with a low initial dose of 2.5 mg once or twice daily, which is then gradually increased (titrated) over several weeks.
Frequency Typically taken once daily. For heart failure, the maintenance dose may be given once daily or in two divided doses.

Procedural Instructions and Special Populations

  • Tablet Administration: Swallow the tablet whole. Do not chew or crush the tablet.
  • Renal Impairment: Patients with reduced kidney function must receive a reduced starting dose (e.g., 2.5 mg) and may require less frequent dosing, as instructed by a healthcare professional.
  • Diuretic Use: To minimize the risk of a sharp drop in blood pressure upon initiation, patients taking diuretics may be instructed to discontinue the diuretic 2 to 3 days prior to starting Pharmapress, if medically permissible.
  • Missed Dose: If a dose is missed, take the next dose at the regular time. Do not take two doses at the same time to compensate for the missed dose.

These instructions define the standardized procedure for the administration of Pharmapress.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pharmapress

The research evidence available for Pharmapress has been gathered through various clinical trials and studies. This summary is intended to provide context on the type of evidence that exists, what outcomes were monitored, and where research limitations or uncertainties remain. Findings described here reflect patterns observed in study groups, and research does not determine whether an individual will respond similarly.


Evidence for Use in High Blood Pressure (Hypertension)

Research for Pharmapress in high blood pressure, or hypertension, was evaluated in Randomized Controlled Trials (RCTs). The main outcomes monitored were changes in systolic and diastolic blood pressure levels and the rate at which participants’ blood pressure values met defined criteria. Findings describe measurements where blood pressure values in the groups receiving Pharmapress were reported to be different from those receiving a placebo. Comparative evidence against all of the newest drug classes currently available is lacking.


Evidence for Use in Symptomatic Heart Failure

The evidence for symptomatic heart failure includes several trials that monitored patients over intermediate and long periods. Research examined clinical outcomes related to systemic or functional imbalance, such as all-cause mortality rates and the frequency of hospitalization for heart failure events. Studies reported how symptoms evolved, and findings describe patterns where the rates of specific major health events were reported in the Pharmapress group compared to the placebo groups over the study period. Data for certain combinations with the most recently approved heart failure treatments are still limited.


What Remains Uncertain About the Evidence

It is important to acknowledge what is not yet fully understood. Evidence quality varies across studies, and there are still areas where more data are needed to draw firm conclusions. The long-term stability of the patterns measured and the full implications of use over decades are still areas where research is ongoing. Additionally, data for certain groups remain insufficient, including for use in pediatric populations and in pregnant patients.

Frequently Asked Questions (FAQ)

Common questions about Pharmapress (FAQ)


Q: What is Pharmapress used for besides the main condition?

According to official documentation, the medication is primarily used for high blood pressure and symptomatic heart failure. In addition to these main uses, the drug is also officially indicated for treating asymptomatic left ventricular dysfunction.


Q: How quickly should I expect Pharmapress to start working?

Official product information indicates that the drug usually begins to take effect within an hour, and the blood pressure-lowering action is generally maintained for at least 24 hours. For some people, several weeks of continuous treatment may be required to achieve the medication's optimal benefit on their blood pressure.


Q: Does Pharmapress cause weight gain or weight loss?

Regulatory documents list anorexia (loss of appetite) as an uncommon side effect. Weight gain or significant weight loss are not listed among the commonly reported side effects in the official safety profile.


Q: Can Pharmapress be taken at the same time as cold or flu medicine?

Official warnings note that this medication interacts with certain components frequently found in cold and flu remedies, specifically non-steroidal anti-inflammatory drugs (NSAIDs) and some decongestants. Combining these may increase the risk of certain side effects or interfere with the drug’s intended effect on blood pressure.


Q: Are there any specific vitamins or supplements that interact with Pharmapress?

Potassium supplements or potassium-containing salt substitutes are specifically listed as a significant interaction risk in official drug information. Their combined use may increase the risk of hyperkalemia (high blood potassium levels).


Q: Is Pharmapress considered a long-term medication?

Official guidelines indicate that this medication is frequently prescribed for the long-term, chronic management of conditions like high blood pressure and heart failure. Continuous, ongoing use is typically required to maintain the therapeutic effect.


Q: Why do some people experience initial drowsiness with Pharmapress?

Official regulatory documents list common central nervous system side effects such as dizziness, lightheadedness, and fatigue, particularly when treatment is first started. These effects are often what patients describe as drowsiness or feeling sleepy.


Q: Does Pharmapress affect blood pressure readings?

The medication is designed to lower blood pressure, and its effect is generally maintained throughout a 24-hour period. While it begins working quickly, the official documentation states that the maximum blood pressure reduction may take several weeks of continuous treatment to achieve.


Q: How does Pharmapress affect sleep patterns?

Official documents list depression and headache as common side effects. While insomnia or specific sleep disturbances are not among the most common adverse reactions, any mood changes could potentially impact sleep.


Q: Is Pharmapress safe to use for older adults (seniors)?

Regulatory guidance includes specific instructions for use in the elderly population. A lower starting dose is typically used, and the dose is adjusted based on the individual's response and kidney function, which is a key part of the regulated use.


Q: Can people with kidney problems use Pharmapress?

Use is generally possible, but regulatory guidance specifies dose adjustment for patients with reduced kidney function, requiring close monitoring. The drug is strictly prohibited with aliskiren in patients who also have kidney impairment.


Q: Can Pharmapress cause stomach upset or nausea?

Yes, official documentation lists gastrointestinal side effects such as nausea and diarrhoea. These effects are listed as Common adverse reactions in the official safety profile.


Q: Is Pharmapress safe for women who are planning to become pregnant?

Due to the severe risk of fetal injury, use of the drug is contraindicated during the second and third trimesters of pregnancy. Therefore, guidance states that patients who are planning a pregnancy should use contraception and discuss their treatment with a healthcare professional before conception.


Q: Are there any known issues with taking Pharmapress and driving?

Because the medication can commonly cause side effects like dizziness, lightheadedness, or fainting, official precautions advise caution regarding driving or operating machinery until the patient knows how the drug affects them.


Q: Is it true that Pharmapress is difficult to stop taking?

Official documentation states that immediately stopping the medication has not been associated with a rapid or uncontrolled increase in blood pressure. However, gradual discontinuation is generally mentioned in relation to stopping treatment.


Q: Do food types matter when taking Pharmapress?

While the medication can be taken with or without food, official product information suggests caution regarding foods that are high in potassium, as the drug can increase the levels of potassium in the blood.


Q: How long does Pharmapress stay in your system after stopping?

The active form of the drug, called enalaprilat, has a terminal elimination half-life of approximately 27 hours. This half-life is the factor that determines how long it generally takes to be cleared from the body.


Q: Are there different forms of Pharmapress, like liquid or extended-release?

Official regulatory documents list the medication as being available in a standard oral tablet form. It is also available as a powder that can be mixed to create an oral solution. No official extended-release formulations are currently specified.


Q: Can Pharmapress cause changes in mood or anxiety?

The official list of common side effects includes depression. While other general mood changes or anxiety are not commonly listed in the main regulatory documents, any effect on the central nervous system should be addressed through standard medical care.


Q: How common are the mild side effects listed for Pharmapress?

The frequency of side effects is officially classified into categories based on occurrence rates. These classifications (e.g., Very Common, Common) are defined by regulatory agencies to indicate the range of frequency in which effects were observed during clinical trials.


Q: Does taking Pharmapress affect laboratory test results?

The medication is known to affect specific laboratory values that require regular monitoring. These include levels of serum potassium and serum creatinine, which is a measure of kidney function.


Q: Is Pharmapress mentioned in any major clinical guidelines?

Yes, official information confirms that the drug and its class (ACE inhibitor) are included and discussed in major established clinical guidelines. These guidelines refer to the drug and its class (ACE inhibitor) for the management of conditions like high blood pressure and chronic heart failure.


Q: Does Pharmapress interact with herbal supplements like St. John's Wort?

Official documents generally advise caution regarding all herbal or complementary medicines, as many are not tested for interaction effects with prescription drugs. No specific interaction with St. John's Wort is commonly listed in the main regulatory documents.


Q: Is it possible to develop a tolerance to Pharmapress over time?

Regulatory reports based on long-term trials indicate that the blood pressure-lowering effects of the medication have been maintained with continuous, prolonged use.


Q: Are there specific times of day when Pharmapress is usually taken?

The medication is typically taken once daily, and the official label states that it can be taken at any time of day, with or without food. This is due to its therapeutic effect being designed to last for at least 24 hours.


Q: Is Pharmapress affected by grapefruit or grapefruit juice?

Official regulatory-compliant information indicates that, unlike some other drug classes, grapefruit or grapefruit juice does not significantly affect the metabolism or effectiveness of this medication.


Q: What are the reasons someone might have to stop taking Pharmapress?

The medication is typically discontinued when certain serious side effects occur, such as symptoms of angioedema (severe swelling of the face or throat). The drug is typically stopped immediately if a patient becomes pregnant, due to the documented risk of fetal injury.


Q: Does Pharmapress affect vision?

Regulatory documents list blurred vision as one of the more common side effects of the medication.

How should Pharmapress be stored and disposed of?

How to Store and Dispose of Pharmapress?

Storage Category Official Requirement
Temperature Store at room temperature and keep from freezing.
Environmental Protection Keep the medicine in its closed container and protect it from heat, moisture, and direct light.
Safety Must be stored out of the reach and sight of children.

Disposal Instructions

Unused or expired Pharmapress should ideally be disposed of through a drug take-back program. This is the method preferred by regulatory authorities for the safe removal of pharmaceuticals from the home.

If a take-back program is unavailable and the medicine is not on the official flush list, it should be prepared for household trash. This involves mixing the medication with an undesirable substance, such as dirt or used coffee grounds, placing the mixture in a sealed container, and then discarding it in the trash. Do not flush this medication down a toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pharmapress found in:

A-Z Index: